1. Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
- Author
-
Nobuyuki Shibusawa, Shunichi Matsumoto, Masanobu Yamada, Takuya Tomaru, Sumiyasu Ishii, Kazuhiko Horiguchi, Atsushi Ozawa, Erina Yuasa-Shibasaki, Tetsurou Satoh, and Aya Osaki
- Subjects
Adult ,glucocorticoid supplementation ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,Nausea ,chemistry.chemical_element ,Case Report ,030209 endocrinology & metabolism ,Calcium ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Adrenal insufficiency ,Humans ,Medroxyprogesterone acetate ,medroxyprogesterone acetate ,Endometrial stromal sarcoma ,business.industry ,General Medicine ,medicine.disease ,Discontinuation ,Withholding Treatment ,chemistry ,030220 oncology & carcinogenesis ,Hypercalcemia ,Vomiting ,Female ,medicine.symptom ,adrenal insufficiency ,business ,Glucocorticoid ,medicine.drug - Abstract
A 39-year-old woman was admitted to our hospital with symptoms of general fatigue, nausea, and vomiting that appeared three months after she stopped seven years of medroxyprogesterone acetate (MPA) medication for endometrial stromal sarcoma. Laboratory tests demonstrated moderate hypercalcemia. Several tests demonstrated that she was suffering from adrenal insufficiency. Glucocorticoid supplementation decreased her calcium level to a normal range, indicating that hypercalcemia was induced by adrenal insufficiency. It was suggested that she was suffering from MPA-induced adrenal insufficiency, but hypocortisolemia was being compensated by a high dose of MPA; hypocortisolemia and hypercalcemia then became evident after MPA treatment was discontinued.
- Published
- 2018